Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Orchestra BioMed Holdings, Inc. (OBIO)

Orchestra BioMed closes $86.3 million stock offering after option exercised in full

Neutral Impact 3 of 5 financing

Orchestra BioMed sold 15,000,000 shares of common stock at $5.00 per share under an underwritten public offering priced November 5, 2026, and the offering closed November 9, 2026. The underwriters' 2,250,000-share option was exercised in full on November 6, 2026, and the filing puts gross proceeds at approximately $86.3 million before underwriting discounts and expenses, with the company citing the AVIM Therapy program, the BACKBEAT pivotal trial, and the Virtue SAB program as intended uses.

Key points

  • Offering: 15,000,000 shares at $5.00 per share, priced November 5, 2026, with Piper Sandler and TD Securities as representatives of the underwriters
  • Underwriters' 30-day option for 2,250,000 additional shares was exercised in full on November 6, 2026
  • Gross proceeds of approximately $86.3 million before underwriting discounts, commissions and other offering expenses; offering closed November 9, 2026
  • Stated uses: AVIM Therapy program, BACKBEAT global pivotal trial, Virtue SAB program and its coronary in-stent restenosis trial, other product candidates, and working capital

The filing

CompanyOrchestra BioMed Holdings, Inc. (OBIO)
Form8-K, current report
Filed with the SECNov 9, 2026, 4:15 PM ET
Accession number0001104659-26-124502

Items reported: 1.01 Material Definitive Agreement7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 7:16 PM ET, from this filing only.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.